Astria Therapeutics (NASDAQ:ATXS – Get Free Report) posted its quarterly earnings data on Monday. The biotechnology company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05), Yahoo Finance reports.
Astria Therapeutics Trading Up 7.6 %
ATXS traded up $0.74 during trading on Tuesday, reaching $10.50. 138,510 shares of the company were exchanged, compared to its average volume of 740,774. Astria Therapeutics has a 52 week low of $4.26 and a 52 week high of $16.90. The firm has a 50 day moving average of $10.03 and a 200 day moving average of $11.38. The stock has a market cap of $576.59 million, a P/E ratio of -4.54 and a beta of 0.73.
Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on ATXS shares. TD Cowen started coverage on shares of Astria Therapeutics in a research report on Monday, July 29th. They set a “buy” rating and a $35.00 price target on the stock. Wedbush reissued an “outperform” rating and set a $22.00 price target on shares of Astria Therapeutics in a research report on Tuesday. Oppenheimer raised their price objective on Astria Therapeutics from $25.00 to $26.00 and gave the stock an “outperform” rating in a research note on Tuesday. Finally, HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a report on Tuesday. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $25.20.
Astria Therapeutics Company Profile
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
Read More
- Five stocks we like better than Astria Therapeutics
- What Do S&P 500 Stocks Tell Investors About the Market?
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- How to Use Stock Screeners to Find Stocks
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
- Consumer Discretionary Stocks Explained
- 3 Small Cap Stocks Insiders Are Actively Buying
Receive News & Ratings for Astria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.